21 CFR 111.553: Complaint Handling for Supplement Makers

An FDA investigator sitting across from your quality manager during an inspection is going to ask for the complaint file early, often before the batch records. A batch record shows what you planned to do. A complaint file shows what happened when something went wrong and whether anyone in the building noticed. For dietary supplement manufacturers, that file, and the procedure behind it, is governed by a narrow slice of 21 CFR Part 111: Subpart O, titled simply "Product Complaints."

The regulation named in the title, 21 CFR 111.553, is the shortest section in that subpart and, in my experience, the most misunderstood. It doesn't describe what to do with a complaint once one arrives. It requires that you have a written procedure covering the whole subpart before one ever does. The actual mechanics of review, investigation, and recordkeeping live in the two sections that follow it: 111.560 and 111.570. Get the relationship between the three backward, and you end up with a complaint log that looks fine sitting in a drawer and falls apart the moment an investigator asks to see the procedure behind it.

I'm Jared Clark, a GMP compliance consultant at Certify Consulting. This guide walks through what 111.553 actually requires, what has to happen once a complaint comes in, what the written record has to contain, and where I most often see supplement manufacturers get this subpart wrong.

What 21 CFR 111.553 Actually Requires

The full text of 21 CFR 111.553 reads: "You must establish and follow written procedures to fulfill the requirements of this subpart O." That's the entire section. No subsections, no list of required elements.

What makes it easy to underestimate is exactly what makes it get cited on Form 483s: it's a general procedural requirement sitting in front of two much more specific sections, and FDA investigators use it to test whether your complaint handling is actually a system or just a folder. A firm can have a complaint log, a customer service inbox, and a habit of calling back unhappy customers, and still fail 111.553 if none of that is written down as a procedure that says who receives complaints, how they get logged, who decides whether an investigation is warranted, and how the finding gets documented. The written procedure is the thing that turns ad hoc customer service into a cGMP control.

In practice, a compliant procedure under 111.553 needs to answer, in writing:

• Who receives product complaints, regardless of channel (phone, email, social media, a returned product, a distributor forwarding a customer email)
• How a complaint gets logged and within what timeframe
• Who qualifies as the "qualified person" responsible for review under 111.560
• The criteria that trigger a full investigation versus a documented no-investigation decision
• How quality control personnel approve both the investigation decision and the findings
• How the written record gets completed, filed, and retained

What Counts As A "Product Complaint" Under Part 111

Before a procedure can work, it has to define what it's catching. Part 111's general definitions section, 21 CFR 111.3, defines a product complaint as "any communication that contains any allegation, written, electronic, or oral, expressing concern, for any reason, with the quality of a dietary supplement, that could be related to current good manufacturing practice." That definition is deliberately wide. It doesn't require a formal complaint form. It doesn't require the complainant to allege illness or injury. It doesn't even require the concern to turn out to be valid.

A verbal complaint about taste or texture, logged nowhere, is still a product complaint under 21 CFR 111.3. The regulation makes no distinction between how the concern arrived and whether it has to be captured. That single sentence is why so many supplement companies fail this subpart: their customer service team fields dozens of calls a month about taste, smell, capsule color, or a broken seal, resolves most of them with a replacement bottle, and never routes a single one into the quality system, because nobody told them a refund request and a cGMP record are the same event.

Examples that qualify as product complaints under 111.3 include:

• Unusual taste, odor, or color
• A broken, missing, or tampered seal
• Foreign material found in a capsule, tablet, or powder
• A label that doesn't match the product inside the bottle
• An illness or adverse reaction reported by a consumer
• A count discrepancy (fewer capsules than the label states)
• A capsule or tablet that appears cracked, discolored, or degraded

The Three Sections That Make Up Subpart O

Subpart O contains exactly three sections, and each one does a different job. Reading 111.553 in isolation is where most of the confusion starts.

Who Has To Review And Investigate A Complaint

21 CFR 111.560 puts the substantive obligation on a "qualified person," a term Part 111 uses throughout to mean someone with the education, training, or experience to perform the task correctly. Under 111.560(a), that person must review all product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, or any other requirement of Part 111. If it does, the same qualified person must investigate.

That review-then-investigate structure matters because it means not every complaint requires a full investigation, but every complaint requires a documented review that reaches a conclusion one way or the other. A taste complaint that, on review, doesn't point to a specification failure can be closed without a formal investigation. What it cannot do is disappear without anyone recording that the review happened and what it concluded.

Two additional requirements in 111.560 tend to surprise manufacturers building their first procedure:

Quality control has to approve the decision, not just the outcome. Under 111.560(b), quality control personnel must review and approve decisions about whether to investigate a product complaint, in addition to reviewing and approving the findings and follow-up action once an investigation is performed. That's two separate QC sign-offs: one on the decision not to investigate (or to investigate), and one on what the investigation found. A procedure that only has QC sign off on closed investigations misses half the requirement.

The investigation has to reach beyond the complained-about unit. 111.560 requires that the review and investigation "must extend to all relevant batches and records." A complaint about a foreign object in one bottle is not just a question about that bottle. If the root cause traces to a filling line issue, every batch that ran through that line during the relevant window is in scope, and the batch production records for those batches are part of what gets pulled and reviewed.

What The Written Complaint Record Must Contain

21 CFR 111.570 is where the paperwork obligation lives, and it's specific. Under 111.570(b)(2), you must keep "a written record of every product complaint that is related to good manufacturing practice." The person who performs any step of the review or investigation must document, at the time of performance, that the step was performed, not reconstruct it later from memory when an FDA investigator asks.

The written record itself must include six elements, laid out in 111.570(b)(2)(ii):

1. The name and description of the dietary supplement
2. The batch, lot, or control number, if available
3. The date the complaint was received, and the complainant's name, address, or telephone number, if available
4. The nature of the complaint, including how the product was used if that's known
5. The reply given to the complainant, if any
6. The findings of the investigation and the follow-up action taken, when an investigation is performed

Those six elements turn a customer's phone call into a document FDA can trace back to a specific batch, a specific date, and a specific quality decision. Miss the batch or lot number and you've lost the thread that would let an investigator, or you, connect a pattern of complaints to a single production run. That's usually the difference between a contained issue and one that widens into a recall investigation.

How Long You Have To Keep Complaint Records

21 CFR 111.570(a) points to Subpart P, Part 111's general recordkeeping rules, for retention. Under 21 CFR 111.605, records must be kept for one year past the shelf life date, if the product carries one, or two years beyond the date of distribution of the last batch associated with the record if it doesn't. Records can be kept as originals, true copies (photocopies, microfilm, microfiche, or other accurate reproductions), or electronic records, and any electronic recordkeeping system has to meet the requirements of 21 CFR Part 11.

Product Complaints vs. Serious Adverse Events: Two Different Clocks

This is where I see the most confusion in practice, including among companies that have a solid 111.553 procedure. A product complaint under Part 111 and a serious adverse event report are related but legally distinct obligations, running on different statutes and different clocks.

Serious adverse event reporting comes from the Dietary Supplement and Nonprescription Drug Consumer Protection Act, codified at 21 U.S.C. § 379aa-1, not from Part 111 at all. Under that statute, once a manufacturer determines a report involves a serious adverse event, it must submit the report to FDA no later than 15 business days after receipt, using the MedWatch form. Records related to each serious adverse event report have to be maintained for six years, a full four years longer than the standard Part 111 retention period.

What this means operationally: every serious adverse event is also a product complaint under 111.3, so it has to move through your Subpart O procedure. But not every product complaint is a serious adverse event, and the moment one is identified as such, it triggers a second, faster, statutorily separate clock with its own reporting form and its own longer retention requirement. A single intake procedure has to be able to split traffic between the two the moment a report comes in describing hospitalization, a life-threatening condition, disability, or a similar serious outcome.

Where Complaint Files Break Down During FDA Inspections

Across the audits and inspection prep engagements I've run, the same handful of gaps show up in complaint files more than any others:

• No written procedure at all, or one that only describes the complaint log, without addressing who qualifies as the reviewer, the investigation trigger, or QC's dual approval role.
• Verbal complaints that never get logged because customer service treats a refund or replacement as the resolution and never routes the underlying concern into the quality system.
• Missing batch or lot numbers on complaint records, because the intake form doesn't require the customer service rep to ask for it or check the returned product.
• A single QC approval instead of two, with sign-off only on the closed investigation and no documented approval of the initial decision not to investigate.
• Investigations that stop at the complained-about unit instead of extending to all batches run on the same line or with the same lot of a component, as 111.560(c) requires.
• No mechanism to distinguish a serious adverse event from a routine complaint at intake, which risks missing the 15-business-day MedWatch clock entirely.

Building A Complaint-Handling SOP That Survives An Audit

If you're writing or revising your Subpart O procedure, work through this in order:

1. Define every intake channel in the procedure: phone, email, web form, social media, a distributor or retailer forwarding a consumer complaint, and a returned product arriving without a complaint form attached.
2. Name the qualified person(s) responsible for review under 111.560, and describe the training or experience that qualifies them.
3. Write the investigation-trigger criteria: what makes a complaint a possible specification failure versus a resolved customer service matter.
4. Build in two separate QC approval steps: one for the decision on whether to investigate, one for the findings and follow-up.
5. Require the six 111.570(b)(2)(ii) elements on every complaint record, with the batch or lot number field marked mandatory whenever the product is available.
6. Add a serious-adverse-event screening question at intake, tied to the 15-business-day MedWatch reporting clock under 21 U.S.C. § 379aa-1.
7. Set the retention rule explicitly: one year past shelf life, or two years past distribution, per 111.605, and six years for anything tied to a serious adverse event.
8. Extend the investigation scope in writing to all relevant batches and records, not just the unit named in the complaint.

A complaint file built this way does something more than satisfy 111.553. It gives you an early warning system for the kind of pattern, three complaints about the same lot, a cluster of foreign-material reports from one production week, that a good quality system is supposed to catch before FDA does. If you're preparing for an inspection and haven't pressure-tested your complaint file against these six elements, our FDA inspection prep guidance walks through what investigators actually pull first. And if Subpart O is one gap among several in a broader Part 111 program, our dietary supplement GMP consulting work starts exactly there: closing the gaps between what your procedures say and what your records can prove.

Frequently Asked Questions

What does 21 CFR 111.553 actually require dietary supplement manufacturers to do? It requires a written procedure covering everything in Subpart O: how complaints are received, reviewed by a qualified person, investigated when warranted, approved by quality control, and documented. The section itself contains no list of required elements; those live in 111.560 and 111.570.

Does a phone call to customer service count as a product complaint under Part 111? Yes. Under 21 CFR 111.3, a product complaint includes any communication, written, electronic, or oral, expressing concern for any reason with the quality of a dietary supplement that could relate to cGMP. A verbal call about taste or a broken seal qualifies just as much as a formal written complaint.

Who decides whether a product complaint requires a full investigation? A qualified person reviews every complaint under 21 CFR 111.560(a) to determine whether it involves a possible failure to meet specifications or another Part 111 requirement. Quality control personnel must separately review and approve that decision, whether the answer is to investigate or not, and later approve the investigation's findings and follow-up action.

How long do dietary supplement manufacturers have to keep complaint records? Under 21 CFR 111.605, standard retention is one year past the product's shelf life date, or two years past the date of distribution if there's no shelf life date. Records tied to a serious adverse event report, governed separately under 21 U.S.C. § 379aa-1, must be kept for six years.

Is a product complaint the same thing as a serious adverse event report? No. Every serious adverse event is a product complaint, but most product complaints are not serious adverse events. Serious adverse event reporting runs under a separate statute with its own 15-business-day reporting deadline to FDA using the MedWatch form and its own six-year retention requirement, distinct from the Part 111 complaint-handling timeline.

Last updated: 2026-09-22